Literature DB >> 27128252

Stabilizing the CH2 Domain of an Antibody by Engineering in an Enhanced Aromatic Sequon.

Wentao Chen1,2, Leopold Kong3, Stephen Connelly3, Julia M Dendle1,2, Yu Liu1,2, Ian A Wilson3,4, Evan T Powers2, Jeffery W Kelly1,2,4.   

Abstract

Monoclonal antibodies (mAbs) exhibiting highly selective binding to a protein target constitute a large and growing proportion of the therapeutics market. Aggregation of mAbs results in the loss of their therapeutic efficacy and can result in deleterious immune responses. The CH2 domain comprising part of the Fc portion of Immunoglobulin G (IgG) is typically the least stable domain in IgG-type antibodies and therefore influences their aggregation propensity. We stabilized the CH2 domain by engineering an enhanced aromatic sequon (EAS) into the N-glycosylated C'E loop and observed a 4.8 °C increase in the melting temperature of the purified IgG1 Fc fragment. This EAS-stabilized CH2 domain also conferred enhanced stability against thermal and low pH induced aggregation in the context of a full-length monoclonal IgG1 antibody. The crystal structure of the EAS-stabilized (Q295F/Y296A) IgG1 Fc fragment confirms the design principle, i.e., the importance of the GlcNAc1•F295 interaction, and surprisingly reveals that the core fucose attached to GlcNAc1 also engages in an interaction with F295. Inhibition of core fucosylation confirms the contribution of the fucose-Phe interaction to the stabilization. The Q295F/Y296A mutations also modulate the binding affinity of the full-length antibody to Fc receptors by decreasing the binding to low affinity Fc gamma receptors (FcγRIIa, FcγRIIIa, and FcγRIIIb), while maintaining wild-type binding affinity to FcRn and FcγRI. Our results demonstrate that engineering an EAS into the N-glycosylated reverse turn on the C'E loop leads to stabilizing N-glycan-protein interactions in antibodies and that this modification modulates antibody-Fc receptor binding.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27128252      PMCID: PMC4852379          DOI: 10.1021/acschembio.5b01035

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  68 in total

1.  Nonnative aggregation of an IgG1 antibody in acidic conditions, part 2: nucleation and growth kinetics with competing growth mechanisms.

Authors:  Rebecca K Brummitt; Douglas P Nesta; Liuquan Chang; Andrew M Kroetsch; Christopher J Roberts
Journal:  J Pharm Sci       Date:  2011-01-06       Impact factor: 3.534

2.  Analysis of site-specific N-glycan remodeling in the endoplasmic reticulum and the Golgi.

Authors:  Ivan Hang; Chia-wei Lin; Oliver C Grant; Susanna Fleurkens; Thomas K Villiger; Miroslav Soos; Massimo Morbidelli; Robert J Woods; Robert Gauss; Markus Aebi
Journal:  Glycobiology       Date:  2015-08-03       Impact factor: 4.313

3.  Classification and characterization of therapeutic antibody aggregates.

Authors:  Marisa K Joubert; Quanzhou Luo; Yasser Nashed-Samuel; Jette Wypych; Linda O Narhi
Journal:  J Biol Chem       Date:  2011-03-25       Impact factor: 5.157

4.  Glycosylation of the enhanced aromatic sequon is similarly stabilizing in three distinct reverse turn contexts.

Authors:  Joshua L Price; David L Powers; Evan T Powers; Jeffery W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-08       Impact factor: 11.205

5.  A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin.

Authors:  Jens C Krause; Tshidi Tsibane; Terrence M Tumpey; Chelsey J Huffman; Christopher F Basler; James E Crowe
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

6.  N-glycosylation of enhanced aromatic sequons to increase glycoprotein stability.

Authors:  Joshua L Price; Elizabeth K Culyba; Wentao Chen; Amber N Murray; Sarah R Hanson; Chi-Huey Wong; Evan T Powers; Jeffery W Kelly
Journal:  Biopolymers       Date:  2012-02-03       Impact factor: 2.505

7.  Enhanced Aromatic Sequons Increase Oligosaccharyltransferase Glycosylation Efficiency and Glycan Homogeneity.

Authors:  Amber N Murray; Wentao Chen; Aristotelis Antonopoulos; Sarah R Hanson; R Luke Wiseman; Anne Dell; Stuart M Haslam; David L Powers; Evan T Powers; Jeffery W Kelly
Journal:  Chem Biol       Date:  2015-07-16

8.  The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs.

Authors:  Derry C Roopenian; Gregory J Christianson; Thomas J Sproule; Aaron C Brown; Shreeram Akilesh; Nadja Jung; Stefka Petkova; Lia Avanessian; Eun Young Choi; Daniel J Shaffer; Peter A Eden; Clark L Anderson
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

9.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

10.  Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1.

Authors:  Shigeki Matsumiya; Yoshiki Yamaguchi; Jun-ichi Saito; Mayumi Nagano; Hiroaki Sasakawa; Shizuo Otaki; Mitsuo Satoh; Kenya Shitara; Koichi Kato
Journal:  J Mol Biol       Date:  2007-02-22       Impact factor: 5.469

View more
  10 in total

Review 1.  Heat denaturation of the antibody, a multi-domain protein.

Authors:  Yoko Akazawa-Ogawa; Hidenori Nagai; Yoshihisa Hagihara
Journal:  Biophys Rev       Date:  2017-12-18

2.  Comprehensive elucidation of the structural and functional roles of engineered disulfide bonds in antibody Fc fragment.

Authors:  Fang Zeng; Chunpeng Yang; Xinyu Gao; Xuan Li; Zhe Zhang; Rui Gong
Journal:  J Biol Chem       Date:  2018-10-16       Impact factor: 5.157

3.  Chemico-Pharmacological Screening of the Methanol Extract of Gynura nepalensis D.C. Deciphered Promising Antioxidant and Hepatoprotective Potentials: Evidenced from in vitro, in vivo, and Computer-Aided Studies.

Authors:  Nishan Chakrabarty; Hea-Jong Chung; Rashedul Alam; Nazim Uddin Emon; Safaet Alam; Mohammed Fazlul Kabir; Md Minarul Islam; Seong-Tshool Hong; Tapas Sarkar; Md Moklesur Rahman Sarker; Mohammad Manjur Rahman
Journal:  Molecules       Date:  2022-05-27       Impact factor: 4.927

Review 4.  A synopsis of recent developments defining how N-glycosylation impacts immunoglobulin G structure and function.

Authors:  Yoshiki Yamaguchi; Adam W Barb
Journal:  Glycobiology       Date:  2020-03-20       Impact factor: 4.313

Review 5.  Glycoengineering Chinese hamster ovary cells: a short history.

Authors:  Roberto Donini; Stuart M Haslam; Cleo Kontoravdi
Journal:  Biochem Soc Trans       Date:  2021-04-30       Impact factor: 5.407

6.  Impact of Drug Conjugation on Thermal and Metabolic Stabilities of Aglycosylated and N-Glycosylated Antibodies.

Authors:  Sayumi Yamazoe; Srikanth Kotapati; Jason M Hogan; Sean M West; Xiaodi A Deng; S J Diong; Jaren Arbanas; Thien Anh Nguyen; Aarti Jashnani; Diksha Gupta; Arvind Rajpal; Gavin Dollinger; Pavel Strop
Journal:  Bioconjug Chem       Date:  2022-03-28       Impact factor: 6.069

7.  Is SARS-CoV-2 Neutralized More Effectively by IgM and IgA than IgG Having the Same Fab Region?

Authors:  Yalcin Pisil; Zafer Yazici; Hisatoshi Shida; Tomoyuki Miura
Journal:  Pathogens       Date:  2021-06-13

Review 8.  Engineering of Fc Fragments with Optimized Physicochemical Properties Implying Improvement of Clinical Potentials for Fc-Based Therapeutics.

Authors:  Chunpeng Yang; Xinyu Gao; Rui Gong
Journal:  Front Immunol       Date:  2018-01-08       Impact factor: 7.561

9.  An oligosaccharyltransferase from Leishmania major increases the N-glycan occupancy on recombinant glycoproteins produced in Nicotiana benthamiana.

Authors:  Alexandra Castilho; Gernot Beihammer; Christina Pfeiffer; Kathrin Göritzer; Laura Montero-Morales; Ulrike Vavra; Daniel Maresch; Clemens Grünwald-Gruber; Friedrich Altmann; Herta Steinkellner; Richard Strasser
Journal:  Plant Biotechnol J       Date:  2018-03-25       Impact factor: 9.803

10.  An engineered human IgG1 CH2 domain with decreased aggregation and nonspecific binding.

Authors:  Guangcan Cao; Xinyu Gao; Yancheng Zhan; Qingguang Wang; Zhe Zhang; Dimiter S Dimitrov; Rui Gong
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.